MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study by Peterfy, C et al.
EXTENDED REPORT
MRI assessment of suppression of structural
damage in patients with rheumatoid arthritis
receiving rituximab: results from the randomised,
placebo-controlled, double-blind RA-SCORE study
Charles Peterfy,1 Paul Emery,2 Paul P Tak,3* Mikkel Østergaard,4 Julie DiCarlo,1
Kati Otsa,5 Federico Navarro Sarabia,6 Karel Pavelka,7 Marie-Agnes Bagnard,8
Lykke Hinsch Gylvin,8 Corrado Bernasconi,8 Annarita Gabriele8
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2014-206015).
For numbered affiliations see
end of article.
Correspondence to
Professor Charles Peterfy, Spire
Sciences, Inc., 5314 Boca
Marina Circle North, Boca
Raton, FL 33487, USA;
charles.peterfy@spiresciences.
com
Received 30 May 2014
Revised 24 September 2014
Accepted 5 October 2014
Published Online First
29 October 2014
To cite: Peterfy C, Emery P,
Tak PP, et al. Ann Rheum
Dis 2016;75:170–177.
ABSTRACT
Objective To evaluate changes in structural damage
and joint inflammation assessed by MRI following
rituximab treatment in a Phase 3 study of patients with
active rheumatoid arthritis (RA) despite methotrexate
(MTX) who were naive to biological therapy.
Methods Patients were randomised to receive two
infusions of placebo (n=63), rituximab 500 mg (n=62),
or rituximab 1000 mg (n=60) intravenously on days 1
and 15. MRI scans and radiographs of the most
inflamed hand and wrist were acquired at baseline,
weeks 12 (MRI only), 24 and 52. The primary end point
was the change in MRI erosion score from baseline at
week 24.
Results Patients treated with rituximab demonstrated
significantly less progression in the mean MRI erosion
score compared with those treated with placebo at
weeks 24 (0.47, 0.18 and 1.60, respectively, p=0.003
and p=0.001 for the two rituximab doses vs placebo)
and 52 (−0.30, 0.11 and 3.02, respectively; p<0.001
and p<0.001). Cartilage loss at 52 weeks was
significantly reduced in the rituximab group compared
with the placebo group. Other secondary end points
of synovitis and osteitis improved significantly with
rituximab compared with placebo as early as 12 weeks
and improved further at weeks 24 and 52.
Conclusions This study demonstrated that rituximab
significantly reduced erosion and cartilage loss at week
24 and week 52 in MTX-inadequate responder patients
with active RA, suggesting that MRI is a valuable tool
for assessing inflammatory and structural damage in
patients with established RA receiving rituximab.
Trial registration number NCT00578305
INTRODUCTION
Inhibition of structural joint damage is a primary
goal of rheumatoid arthritis (RA) therapy, and a
number of disease-modifying antirheumatic drugs
(DMARDs), including rituximab, have demon-
strated this ability.1–5 While assessment of structural
damage has traditionally been performed using
radiography, the importance of earlier and more
sensitive joint imaging has been recognised by
recent guidelines.1 6 7
Although more expensive than radiography, MRI
can simultaneously assess all relevant structures in
the inflamed joint and is more sensitive at detecting
bone erosions, allowing for smaller and shorter
clinical trials.6 7 Furthermore, MRI visualises
articular cartilage loss directly, whereas radiography
evaluates cartilage loss indirectly through joint-
space narrowing. MRI can also detect joint inflam-
mation, which is particularly useful when assessing
early or undifferentiated joint disease.8 9
Rituximab is approved in the European Union
and the USA for the treatment of RA after inad-
equate response (IR) to ≥1 tumour necrosis factor
(TNF) inhibitor. The approved dose of rituximab
for the treatment of RA is two 1000-mg intraven-
ous infusions separated by 2 weeks every 24 weeks
or based on clinical evaluation, but not sooner than
every 16 weeks. Rituximab inhibits joint damage
progression in the indicated patient population,
those with an IR to anti-TNF therapies (TNF-IR),
and non-indicated populations.2 3 10
This study evaluated changes in structural
damage and joint inflammation assessed by MRI
following rituximab treatment in patients with
active RA despite methotrexate (MTX) who were
naive to biological therapy.
METHODS
Study design and patients
RA-SCORE was a phase 3b, randomised, placebo-
controlled, double-blind, multicentre, international
study. Patients met the American College of
Rheumatology (ACR) criteria for RA with a disease
duration ≥3 months and ≤10 years, had active RA
(Disease Activity Score in 28 joints (DAS28) C react-
ive protein score ≥3.2), and had experienced an IR
to MTX (MTX-IR) at a dose of 12.5–25 mg/week
for ≥12 weeks, with the last 4 weeks before baseline
maintained at a stable dose. Minimal MTX doses of
7.5 mg/week or 10 mg/week were permitted only in
cases of documented intolerance to higher doses.
Patients were biological naive and were either posi-
tive for anticyclic citrullinated protein (≥20 U) or
for rheumatoid factor (≥20 IU/mL). Patients were
also required to have erosion and/or clinical signs
and symptoms of synovitis in a single (MRI) joint
(metacarpophalangeal and/or wrist). In patients
with a disease duration of >1 year, clinical evidence
of synovitis and ≥1 definitive radiographic erosion
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at screening based on central review were required. In those with
disease duration of ≤1 year, clinical synovitis needed to be con-
firmed by MRI at baseline. Key exclusion criteria included a
history of rheumatic autoimmune disease other than RA or sig-
nificant systemic involvement secondary to RA. Secondary
Sjögren’s syndrome and secondary limited cutaneous vasculitis
with RAwere permitted.
Patients were randomised in a 1:1:1: ratio to receive two infu-
sions of placebo, rituximab 500 mg, or rituximab 1000 mg
intravenously on days 1 and 15. Premedication with analgesics,
antihistamines and intravenous methylprednisolone 100 mg
were required before each rituximab infusion. Patients contin-
ued to receive stable doses of MTX and folic acid/folate
(≥5 mg/week). Concomitant oral glucocorticoids (at a stable
dose ≤10 mg/day) were allowed; intra-articular glucocorticoid
injections could be used in a limited fashion to treat severe RA
flares. Rescue therapy, or increased dose of MTX or use of non-
biological DMARDs, was permitted at week 16 for patients
with <20% improvement in tender and swollen joint counts
compared with baseline. Rituximab retreatment was permitted
after week 24 if patients had a DAS28 C reactive protein score
≥2.6 and no contraindications to treatment (such as active
infections).
This study was conducted in accordance with the Declaration
of Helsinki and the International Conference on Harmonisation
Harmonised Tripartite Guideline for Good Clinical Practice
(NCT00578305). The protocol and any accompanying material
provided to the patient were approved by an Independent
Ethics Committee or Institutional Review Board before starting
the study. Patients provided written informed consent before
enrolment.
Efficacy assessments
Patients returned for efficacy and safety assessments at weeks 4,
6, 12, 16, 24, 36, 44 and 52. MRI scans and radiographs were
acquired at baseline (within 14 days before the first study medi-
cation infusion) and at weeks 12 (MRI only), 24 and 52. The
most clinically inflamed hand and wrist (or the dominant hand,
in case of equal inflammation) were imaged with a 1.5-Tesla
whole-body MRI scanner using a commercial surface coil and
an acrylic frame11 designed to ensure proper and reproducible
positioning of the hand and wrist. The hand and wrist were
scanned separately using coronal short-tau inversion recovery
and coronal fat-suppressed three-dimensional gradient echo
with and without intravenous gadolinium-based contrast agent.
The same hand and wrist were used for all assessments.
All images were scored centrally by two independent radiolo-
gists who were blind to treatment allocations, clinical informa-
tion and the order in which serial images were acquired. MRI
images were scored using the Outcome Measures in
Rheumatology Clinical Trials RA MRI Scoring (RAMRIS)
method.6 12–14 Cartilage loss determined by MRI was assessed
using a previously validated 9-point cartilage loss scale
(CARLOS).11 15 Radiographs of hands and both feet were
scored using the Genant-modified Sharp method.16
No progression was defined as a change from baseline in
the RAMRIS erosion score of ≤0. Total damage scores were
calculated using the following formula: RAMRIS erosion
score+(2.5×CARLOS).15 Total inflammation scores were
calculated using the following formula: RAMRIS osteitis
score+(3×RAMRIS synovitis score).
Clinical efficacy parameters included ACR 20/50/70 and
European League Against Rheumatism (EULAR) response rates
and change from baseline in the DAS28-erythrocyte
sedimentation rate (DAS28-ESR) and in the Health Assessment
Questionnaire Disability Index (HAQ-DI). Safety parameters
included treatment-emergent adverse events (AEs), clinical
laboratory parameters, and human antichimeric antibody
(HACA) to rituximab at week 24.
Statistical analyses
The intent-to-treat population was defined as all patients who
were randomised and received any part of an infusion, with
analysis groups defined according to randomisation. The safety
population included all patients who received any part of an
infusion, analysed according to the treatment received.
Additional details are provided in online supplementary text 1.
In the primary analysis, the change in RAMRIS erosion score
from baseline at week 24 (primary end point) was compared
between patients receiving rituximab 1000 mg and those receiv-
ing placebo. Secondary end points included changes from base-
line in the RAMRIS erosion score at weeks 12 and 52; RAMRIS
synovitis and osteitis at weeks 12, 24 and 52; and proportions
of patients with no progression in RAMRIS erosion score at
weeks 24 and 52. Post hoc analyses evaluated for total inflam-
mation scores at weeks 12, 24 and 52 and change in CARLOS
and total damage scores at weeks 24 and 52.
The van Elteren test stratified for the factors used at randomisa-
tion (duration of MTX use < or ≥6 months and presence of bone
erosions) was used for the primary analysis and to assess changes
from baseline in RAMRIS erosion scores, Genant-modified Sharp
radiographic erosion scores and CARLOS (imputation by linear
extrapolation), and to assess changes from baseline in RAMRIS
synovitis and osteitis scores (last observation carried forward).
The Cochran-Mantel-Haenszel test was used to assess the propor-
tions of patients with no newly eroded joints (no imputation
used), of patients with no progression of erosions, of patients
with improvements in synovitis and osteitis, and of patients











Female, n (%) 48 (76.2) 45 (72.6) 50 (83.3)
Age, mean (SD), years 50.3 (11.9) 48.7 (11.1) 50.7 (11.7)
RA duration, mean (SD), years 4.4 (3.1) 4.5 (2.9) 4.9 (2.9)
MTX dose, mean (SD), mg/wk 16.8 (3.3) 15.8 (4.0) 15.2 (3.5)
Concomitant CS, n (%) 35 (55.6) 33 (53.2) 35 (58.3)
SJC, mean (SD) 11.4 (6.1) 12.5 (7.1) 10.9 (5.9)
TJC, mean (SD) 14.9 (6.7) 15.2 (7.5) 14.0 (6.9)
DAS28-CRP, mean (SD) 5.6 (1.1) 5.6 (1.1) 5.3 (1.0)
DAS28-ESR, mean (SD) 6.3 (1.1) 6.3 (1.2) 6.0 (1.1)
HAQ-DI, mean (SD) 1.5 (0.8) 1.4 (0.7) 1.3 (0.7)
RAMRIS erosion score, mean (SD) 14.1 (13.4) 13.2 (12.0) 12.7 (12.0)
CARLOS, mean (SD) 5.9 (9.4) 8.1 (10.4) 7.8 (10.9)
RAMRIS synovitis score, mean (SD) 7.4 (4.8) 7.9 (4.0) 8.1 (4.9)
RAMRIS osteitis score, mean (SD) 6.1 (6.7) 8.8 (9.0) 6.8 (8.3)
Total Genant-modified Sharp
radiographic score, mean (SD)
20.2 (18.9) 17.9 (16.6) 19.8 (18.8)
Annualised radiographic
progression rate, mean (SD)
6.3 (6.7) 6.8 (8.9) 5.7 (7.4)
CARLOS, cartilage loss score; CRP, C reactive protein; CS, corticosteroids; DAS28,
Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI,
Health Assessment Questionnaire Disability Index; MTX, methotrexate; RA,
rheumatoid arthritis; RAMRIS, RA MRI Scoring; SJC, swollen joint count; TJC, tender
joint count.
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achieving a EULAR and ACR 20/50/70 response (non-responder
imputation). Analysis of covariance was used to assess changes
from baseline in DAS28-ESR and HAQ-DI (last observation
carried forward). All tests were two-sided and were conducted at
the 5% significance level without correction for multiplicity.
RESULTS
Patient disposition and baseline characteristics
A total of 283 patients from 37 centres in 17 countries were
screened. Of these, 185 patients were randomised and
received study drug and were therefore included in the
intent-to-treat and safety populations (19 November 2007 to
12 April 2010 from first patient randomised to last patient
visit). Of the patients receiving placebo, 22% failed to com-
plete the study, compared with 5% and 7% of patients receiv-
ing rituximab 500 mg and rituximab 1000 mg, respectively.
The predominant reasons for withdrawal in all treatment
groups were non-safety related (see online supplementary table
S1). Patient disposition is shown in online supplementary
figure S1. The proportion of patients who remained in the
study until week 52 was higher in the rituximab groups than
in the placebo group.
Baseline demographics and disease characteristics were gener-
ally well balanced among the treatment groups (table 1). The
mean age of the patients was 50 years, and the mean disease
duration was slightly less than 5 years. At baseline, the mean
DAS28-ESR was 6.2. Patients were receiving a mean MTX dose
of >15 mg/week, and slightly more than half were receiving
concomitant corticosteroids. Approximately 77% (48/62) and
72% (43/60) of patients in the rituximab 500-mg and rituximab
1000-mg groups, respectively, were retreated with a second
cycle of rituximab after 24 weeks.
Figure 1 Primary end point. (A) Mean change in rheumatoid arthritis MRI Scoring (RAMRIS) erosion score (intent-to-treat (ITT) population).
Missing values were imputed using linear extrapolation. Error bars represent the SE of the mean. (B) Cumulative distribution of change in RAMRIS
erosion score at week 24. Missing values were imputed using linear extrapolation, ITT population. Broken horizontal lines represent ±SDC (smallest
detectable change, determined according to the method of Bruynesteyn, et al.24 SDCs were 1.88 for RAMRIS erosion score, 1.54 for CARLOS, 2.11
for RAMRIS osteitis score and 1.56 for RAMRIS synovitis score).
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Figure 2 Mean changes in rheumatoid arthritis MRI Scoring (RAMRIS) synovitis, RAMRIS osteitis and MRI cartilage loss score (CARLOS)
(intent-to-treat population). (A) Synovitis. Missing values were imputed using last observation carried forward. Error bars represent the SE of the
mean. (B) Osteitis. Missing values were imputed using last observation carried forward. Error bars represent the SE of the mean. (C) Cartilage loss.
Error bars represent the SE of the mean.
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MRI analysis
The analysis of the primary end point showed significantly less
progression in the mean RAMRIS erosion score at week 24 in
patients treated with rituximab 1000 mg compared with those
treated with placebo (figure 1A). Similar results were observed
at week 52. Significant differences were also observed between
the rituximab 500-mg group and the placebo group at weeks 24
and 52. The mean change in RAMRIS erosion score at week 12
was not significantly different between either of the rituximab
groups and the placebo group. The cumulative distribution plots
revealed increased RAMRIS erosion score at week 24 in a
greater proportion of patients in the placebo group than in
either rituximab group (figure 1B).
Patients treated with rituximab 1000 mg demonstrated a pro-
gressively greater decrease in mean RAMRIS synovitis score at
weeks 12, 24 and 52, which was significantly greater than
placebo at each time point (figure 2A). Patients receiving rituxi-
mab 500 mg also showed a progressive decrease in the mean
RAMRIS synovitis score at each time point; the decreases were
numerically less than those in the rituximab 1000 mg-treated
patients and were significantly different from those in the
placebo-treated patients at weeks 24 and 52. The rituximab
1000-mg group demonstrated significantly greater reductions in
RAMRIS osteitis scores compared with those in the placebo
group at weeks 12, 24 and 52; similar results were observed in
the rituximab 500-mg group at each time point (figure 2B).
Mean cartilage loss scores based on CARLOS increased progres-
sively at weeks 24 and 52 in patients treated with placebo,
whereas patients treated with rituximab 1000 mg showed signifi-
cantly greater improvement compared with those who received
placebo (figure 2C) at week 52; a statistically significant differ-
ence was not observed at week 24. Patients receiving rituximab
500 mg demonstrated significantly less cartilage loss compared
with those in the placebo group at weeks 24 and 52.
Patients who received rituximab 1000 mg demonstrated sig-
nificantly better total damage scores compared with those in the
placebo group at weeks 24 and 52 (figure 3A). Similar results
were observed in the rituximab 500-mg group at weeks 24 and
52. Mean decreases in total inflammation score were signifi-
cantly greater in the rituximab 1000-mg group compared with
those in the placebo group as early as week 12 and were main-
tained through weeks 24 and 52 (figure 3B). Similar results
were demonstrated in the rituximab 500-mg group.
The proportion of patients with no worsening of RAMRIS
erosion score was significantly greater in the rituximab 1000-mg
group than in the placebo group at week 24 (table 2) and week
Figure 3 Mean change in total
damage and total inflammation scores.
(A) Total damage score. Total damage
score=erosion score+(2.5×cartilage
loss score). Missing values were
imputed using linear extrapolation
using baseline and week 12 images.
Error bars represent the SE of the
mean. (B) Total inflammation score.
Total inflammation score=osteitis
score+(3×synovitis score). Missing
values were imputed using linear
extrapolation using baseline and week
12 images. Error bars represent the SE
of the mean.
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52. Similar effects were observed for the rituximab 500-mg
group, although the difference was only statistically significant at
the 52-week time point.
Radiographic analysis
At week 52, the analysis of the total radiographic
Genant-modified Sharp score revealed significantly greater
inhibition of radiographic damage in patients in the rituximab
1000-mg and 500-mg groups compared with the placebo group,
although the study was not powered for the comparison of
radiographic end points. The changes in mean erosion score
from baseline were significantly lower in the two active treat-
ment groups compared with that in the control group, whereas
the changes in mean joint-space-narrowing score were numeric-
ally lower in both rituximab groups, but statistically significantly
so in the rituximab 500-mg group
Clinical assessment
Clinical efficacy outcomes are presented in table 2. At weeks 24
and 52, patients who received rituximab 500 mg demonstrated
significantly greater improvements in DAS28-ESR compared
with those who received placebo; those who received 1000 mg
demonstrated numerically greater improvements in DAS28-ESR
scores compared with those who received placebo, but the dif-
ference was not statistically significant at either time point.
Significantly more patients in both rituximab groups achieved
ACR20 and ACR50 compared with patients in the placebo
group at weeks 24 and 52. However, ACR70 rates at weeks 24
and 52 in either rituximab group were not consistently
improved compared with the rate in the placebo group. At
weeks 24 and 52, significantly more patients in the rituximab
1000-mg and 500-mg groups than in the placebo group had
moderate or good EULAR responses. Significant improvements
Table 2 Summary of efficacy outcomes
Placebo+MTX (n=63) Rituximab 500 mg+MTX (n=62) p Value* Rituximab 1000 mg+MTX (n=60) p Value†
Patients with no newly eroded joints, %
Week 24 55.6 77.4 0.011 73.3 0.045
Week 52 60.3 77.4 0.042 66.7 0.455
Patients with no progression of erosions, %‡
Week 24 33.3 50.0 0.055 51.7 0.039
Week 52 27.0 48.4 0.011 55.0 <0.001
Mean change from baseline in Genant-modified Sharp radiographic erosion score
Week 24 0.62 0.21 0.049 0.14 0.097
Week 52 0.99 0.34 0.027 0.14 0.003
Mean change from baseline in Genant-modified Sharp radiographic JSN score
Week 24 0.14 0.09 0.286 0.16 0.796
Week 52 0.38 0.06 0.003 0.15 0.102
Mean change from baseline in total Genant-modified Sharp radiographic score
Week 24 0.76 0.31 0.034 0.30 0.310
Week 52 1.37 0.40 0.010 0.29 0.002
Mean change from baseline in DAS28-ESR
Week 24 −0.85 −1.69 0.007 −1.64 0.277
Week 52 −0.81 −2.08 <0.001 −1.90 0.075
Patients with good EULAR response, %
Week 24 19.0 29.0 0.017 35.0 <0.001
Week 52 7.9 33.9 <0.001 37.3 <0.001
Patients with moderate EULAR response, %
Week 24 22.2 37.1 0.017¶ 42.4 <0.001¶
Week 52 31.7 45.2 <0.001¶ 49.2 <0.001¶
Change from baseline in HAQ-DI score
Week 24 −0.19 −0.425 0.026 −0.44 0.778
Week 52 −0.18 −0.520 0.001 −0.42 0.165
Patients achieving ACR20, %
Week 24 28.6 51.6 0.003 51.7 0.006
Week 52 28.6 67.7 <0.001 68.3 <0.001
Patients achieving ACR50, %
Week 24 11.1 24.2 0.050 26.7 0.013
Week 52 14.3 37.1 0.003 35.0 0.005
Patients achieving ACR70, %
Week 24 1.6 11.3 0.036 8.3 0.085
Week 52 6.3 17.7 0.056 16.7 0.049
*p Value for comparison of rituximab 500 mg versus placebo.
†p Value for comparison of rituximab 1000 mg versus placebo.
‡No progression defined as a change from baseline in the RAMRIS erosion score of ≤0.
¶ p Values consider the three response levels: good, moderate and no response.
ACR 20/50/70, 20%, 50% and 70% improvements in response per the American College of Rheumatology; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation
rate; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire Disability Index; JSN, joint-space narrowing; MTX, methotrexate; RAMRIS, RA MRI
Scoring.
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in HAQ-DI were seen in the rituximab 500-mg group at weeks
24 and 52. Numerical improvements were seen in the 1000-mg
group compared with the placebo group at these time points,
although these changes were not statistically significant.
Safety
The overall safety profiles were similar in both rituximab groups
and are summarised in table 3. The incidence of AEs reported
in the rituximab 1000-mg and 500-mg groups was numerically
lower than that reported in the placebo group, as was the inci-
dence of serious AEs per 100 patient-years. The incidence of
infections was numerically higher in both rituximab groups
compared with that in the placebo group, as was the incidence
of serious infections per 100 patient-years. One patient in the
rituximab 500-mg group reported a serious soft tissue infection
(of suspected bacterial origin), which was treated and resolved
after 11 days. Two serious infections were reported in the rituxi-
mab 1000-mg group: bronchitis and omphalitis due to
Escherichia coli. The two infections resolved following treat-
ment. One endometrial carcinoma was reported in the rituxi-
mab 1000-mg group. No deaths and no life-threatening AEs
were reported. Additional safety data are provided in online
supplementary tables S2 and S3.
The incidence of infusion-related reactions decreased from
0%, 4.8% and 15.0% in the placebo, rituximab 500-mg and
rituximab 1000-mg groups during the first course of rituximab
to 0%, 0% and 5.0% during the second course, respectively.
The maximum Common Toxicity Criteria for Adverse Events
grade of the 13 total events was moderate.
Overall, no safety concerns were raised by the laboratory
data. At week 24, five patients in the rituximab 500-mg group
(10.6%) and one in the rituximab 1000-mg group (3.8%) were
positive for human HACA. At week 52, only one patient (2.8%)
remained positive for HACA in the rituximab 500-mg group,
whereas two patients (6.5%) remained positive for HACA in the
rituximab 1000-mg group.
DISCUSSION
In this placebo-controlled, double-blind, study, we used MRI to
evaluate changes in structural damage and joint inflammation in
MTX-IR patients with active RA who were biologicals-naive and
received MTX plus either rituximab or placebo. The mean
RAMRIS erosion score progressed in the placebo arm over
52 weeks at a rate of approximately 0.3 RAMRIS units per
month, consistent with the rates observed in the placebo arms
of other randomised controlled trials of RA using MRI.17
Cartilage loss also progressed at 24 and 52 weeks in patients
treated with placebo. Compared with placebo, rituximab
1000 mg significantly reduced MRI erosion at 24 weeks
(primary end point) and erosion and cartilage loss at 52 weeks.
The rituximab 500-mg dose demonstrated improvements rela-
tive to placebo that were generally in the same range as
observed with the higher rituximab dose, but the study was not
powered to detect differences between the two doses in the
observed range. The secondary end points of synovitis, osteitis,
cartilage loss, total inflammation and total joint damage scores
each improved significantly with rituximab compared with
placebo as early as 12 weeks, and improved further at weeks 24
and 52. The proportions of patients with no joint damage pro-
gression, with improvements in synovitis and osteitis, and with
moderate or good EULAR response were all significantly higher
with rituximab than with placebo. For some disease activity
indices, such as DAS28 and HAQ-DI, the rituximab 1000-mg
dose demonstrated numerically positive trends, which were not
always statistically significant.
Safety data were consistent with those previously reported for
rituximab in biological-naive patients,3 18 19 and no new safety
signals were detected. AEs were predominantly mild, and few
severe or serious AEs and no deaths were observed with treat-
ment. No major differences between the safety profiles of the
1000-mg and 500-mg doses were observed.
These results are consistent with the findings of previous
studies that used radiography to demonstrate inhibition of joint
damage progression by rituximab,3 5 20 and may be explained
by the inhibitory effect of rituximab treatment on osteoclasto-
genesis.21 Recent EULAR and ACR recommendations recognise
the superiority of MRI to clinical examination at detecting joint
inflammation and recommend the use of MRI to predict
response to treatment.1 7
This study had several strengths. It is the first published
report of MRI’s ability to discriminate suppression of cartilage
loss in a multicentre randomised controlled trial in RA. This is
important because exclusion of the assessment of cartilage loss
in prior clinical trials has been an obstacle to accepting MRI as
a substitute for radiography in clinical trials. Previous studies
have demonstrated that articular cartilage loss is at least as
important as bone erosion in determining long-term disability
in patients with RA,22 and suppression of bone erosion does
not always indicate that cartilage loss has also been sup-
pressed.23 Inclusion of the assessment of cartilage loss in this
study further allowed determination of total joint damage by
MRI, analogous to the Total Sharp Score that is used in RA
clinical trials to assess radiographic joint damage. A limitation
of this study was that suppression of cartilage loss and radio-
graphic outcomes were not measured at week 12, limiting the
ability to compare cartilage loss against bone erosion or dis-
criminate progression between the two imaging techniques.
Additionally, although treatment effects in the rituximab
500-mg and 1000-mg groups largely overlapped, in a few of
the end points (particularly cartilage loss and joint-space nar-
rowing), one or the other dosing arm did not reach statistical
significance compared with placebo. Because this study was not
powered to compare the two active treatment arms, additional
analyses were not performed to explore this apparent discrep-
ancy. Of note, in the IMAGE study, only the approved
2×1000-mg rituximab dosing group exhibited significant
inhibition of radiographic progression compared with the
placebo group, whereas those in the rituximab 500-mg group











Any TEAE 41 (65.1) 35 (56.5) 36 (60.0)
Mild 20 (31.7) 17 (27.4) 13 (21.7)
Moderate 17 (27.0) 18 (29.0) 19 (31.7)
Severe 4 (6.3) − 4 (6.7)
Treatment-related 14 (22.2) 13 (21.0) 9 (15.0)
Any serious TEAE 5 (7.9) 3 (4.8) 4 (6.7)
Events/100 PY 12.0 4.9 6.9
Any infection 16 (25.4) 25 (40.3) 27 (45.0)
Any serious infection − 1 (1.6) 3 (5.0)
Events/100 PY 0.0 1.6 3.4
Death on study − − −
MTX, methotrexate; PY, patient-year; TEAE, treatment-emergent adverse event.
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did not—a treatment effect that was robust to several analyses.3
Lastly, it is important to highlight that patients in this study
were biological naive and DMARD-IR; therefore, the results
cannot be extrapolated to patients with more progressive or
refractory disease, such as TNF-IR patients.
In conclusion, this study demonstrated that rituximab signifi-
cantly reduced erosion and cartilage loss at weeks 24 and 52 in
MTX-IR patients with active RA. These changes were preceded
by reductions in synovitis and osteitis, and explain radiographic
evidence that rituximab+MTX prevents joint damage in
patients with active RA. Our results suggest that MRI is a valu-
able tool for assessing inflammatory and structural damage in
patients with established RA receiving rituximab.
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